A compassionate use program of osimertinib in Japanese patients with histologically proven non-small-cell lung cancer (NSCLC) and harboring the T790M EGFR mutation
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors AstraZeneca
- 02 Jan 2018 New trial record